Physician profile
Thomas H Wang
NPI 1558413971
$6,347.92
in general payments reported to CMS, 2019-2025
39 companies · $625 in 2025
The $625 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,076 · 2020: $832 · 2021: $1,223 · 2022: $853 · 2023: $835 · 2024: $903 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,344 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,344.31 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $757.68 | 2020-2025 | Nexletol |
| Amgen INC. | $662.14 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $585.67 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $572.31 | 2019-2024 | |
| Amarin Pharma, INC. | $479.36 | 2019-2023 | |
| Abbott Laboratories | $462.57 | 2019-2025 | Coroflow, Thoratec Heartmate 3 Lvas Implant Kit, Gallant |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $277.10 | 2019-2024 | Lifevest |
| Inari Medical, INC. | $274.33 | 2020-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astrazeneca Pharmaceuticals LP | $260.41 | 2019-2024 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $250.18 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Janssen Pharmaceuticals, INC | $235.15 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.42 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $165.71 | 2021-2023 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $132.51 | 2024-2025 | |
| Pfizer INC. | $111.21 | 2019-2024 |
Show all 38 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.